The medical community is excited by retatrutide, a new dual GIP and GLP-1 receptor that’s showing remarkable results in clinical studies . This treatment works by replicating natural hormones to affect appetite and promote feelings of fullness , ultimately resulting in substantial fat reduction . While presently under evaluation and not yet avail